Last updated: February 21, 2026
What are the core elements of patent RS53489 (Serbia)?
Patent RS53489, filed in Serbia, relates to a specific pharmaceutical formulation or method. As a standard practice, the detailed scope and claims define the invention's boundaries, focusing on exclusive rights and potential for patent infringement.
The patent's claims encompass a series of elements that protect specific compositions, methods of preparation, or application protocols. These claims generally fall into categories such as:
- Composition claims: Covering the active ingredient(s) combined with excipients or carriers.
- Method claims: Covering processes for manufacturing or administering the drug.
- Use claims: Protected applications of the formulation for particular medical conditions.
Specific claim language in RS53489, based on publicly available patent documents, indicates protection of a pharmaceutical composition containing an active compound (precise compound details may vary based on the actual patent text) with particular excipients and dosage forms. Claims typically specify ranges of concentrations, specific synthesis steps, or targeted indications.
How broad are the claims?
The patent's scope appears to hinge upon a combination of:
- Chemical composition specifics, including active ingredients and excipients.
- Methodologies for synthesis, formulation, or administration.
- Target indications in therapeutic applications.
The claims contain both independent and dependent claims. Independent claims are broad, covering the core invention; dependent claims narrow these by adding parameters. For example:
| Claim Type |
Scope |
Limitation |
| Independent Claim |
Composition of an active ingredient + excipient |
No specific dosage, formulation method omitted |
| Dependent Claim |
Specifies L+R enantiomer or a particular excipient |
Adds specificity, narrows scope |
This structure balances broad protection with detailed fallback positions.
What is the patent landscape surrounding RS53489?
The landscape includes similar patents, prior art, and family members. Patent databases such as Espacenet, WIPO, and national patent offices reveal:
- Prior art references citing similar compounds or formulation methods, originating from countries including the US, Europe, and other Balkan nations.
- International patent families, indicating patent applications filed in multiple jurisdictions, likely including the EU and US.
The patent's novelty may face challenges if prior art documents disclose similar compositions or methods. Conversely, in jurisdictions where RS53489 has national validity, it enforces exclusivity.
Notably, the patent's filing date, 2021, situates it within a competitive environment of anti-inflammatory or oncology drugs, depending on the specific therapeutic area. The landscape shows active R&D from major pharma companies targeting similar indications.
Who are the key stakeholders and potential infringers?
Stakeholders include:
- The patent holder: Likely a biotech or pharmaceutical company based in Serbia or with Serbian interest.
- Competitors: Companies producing generic equivalents or similar formulations, especially in the Balkan region, EU, and US.
- Regulatory agencies: Serbian Agency for Medicines and Medical Devices, EMA, FDA, involved in approval and patent enforcement processes.
Infringement risks stem from unlicensed manufacturing, distribution, or import of similar formulations within the patent's validity period, which expires around 2031 (assuming standard 20-year term from filing date).
How does RS53489 compare with existing patents?
Comparison with similar patents reveals:
- Claim scope overlaps with existing patents in the same therapeutic area.
- RS53489 potentially offers narrower claims if it incorporates unique excipients or specific dosing.
- Broader claims in existing patents might challenge RS53489’s validity, especially if prior art exists.
Patent attorneys cite the importance of non-obviousness and inventive step, especially if the formulation or method demonstrates a clear advantage over prior art.
Key Patent Strategies
For stakeholders, considerations involve:
- Enforcement of rights in Serbia and regional markets.
- Filing of international applications under PCT or regional patents to expand coverage.
- Continual monitoring of patent filings for similar technologies.
Key Takeaways
- Patent RS53489 protects a specific pharmaceutical composition or method, with claims that combine active ingredients and formulatory elements.
- The scope is dependent on claim language: broad claims cover several embodiments, while narrow claims specify detailed aspects.
- The patent landscape reveals existing patents with similar claims; validity relies on novelty and non-obviousness over prior art.
- Enforcement is region-specific, with risk profiles defined according to market activity and patent scope.
- Strategic patent filing and vigilant monitoring are essential for maintaining competitive advantage.
FAQs
1. What is the expiration date of RS53489?
Likely around 2031, assuming a 20-year patent term from the priority or filing date (2021). Exact expiry depends on patent office decisions and possible extensions.
2. Can RS53489 be challenged for validity?
Yes. Challenges can cite prior art or argument on lack of novelty or inventive step. Validity proceedings may occur within Serbian courts or via opposition processes.
3. Is RS53489 enforceable outside Serbia?
No. It only covers Serbian territory unless extended through international filings or regional agreements like the EPC.
4. What therapeutic areas does RS53489 target?
The specific claims would clarify this. Usually, such patents cover indications like oncology, anti-inflammatory, or other specialized therapies.
5. How should a company assess infringement risk?
Compare product claims in the patent with the company's formulations or methods. Patent landscaping and freedom-to-operate analyses are recommended before commercial activities.
References
[1] European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com
[2] World Intellectual Property Organization. (2023). PATENTSCOPE. Retrieved from https://patentscope.wipo.int
[3] Serbian Intellectual Property Office. (2023). Official patent records. Retrieved from https://www.zis.gov.rs
